FIELD: medicine.
SUBSTANCE: group of inventions relates to a monomeric calicheamicin derivative/antibody conjugate, as well as a method for treating an individual with a proliferative disorder other than cell expression of CD22 antigen on surface thereof, comprising administering a therapeutic dose of said conjugate.
EFFECT: claimed conjugate is characterised by significantly higher drug load than previously described methods with a low degree of aggregation and low conjugate fraction (LCF).
32 cl, 29 dwg, 13 tbl, 9 ex
Title | Year | Author | Number |
---|---|---|---|
CONJUGATES "CALIHEAMICIN DERIVATIVE-CARRIER" | 2003 |
|
RU2422157C2 |
CALICHEAMICIN DERIVATIVE-CARRIER CONJUGATES | 2016 |
|
RU2678818C2 |
USING ANTI-CD40-ANTIBODIES | 2008 |
|
RU2491095C2 |
ANTI-PTK7 ANTIBODY-DRUG CONJUGATES | 2015 |
|
RU2708075C2 |
COMBINED THERAPY BASED ON AFUCOSYLATED CD20 ANTIBODY IN COMBINATION WITH CD22 ANTIBODY CONJUGATE - DRUG PREPARATION | 2014 |
|
RU2700092C2 |
ANTI-CD79b ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE THEREOF | 2013 |
|
RU2694688C2 |
METHOD OF TREATING VASCULITIS | 2005 |
|
RU2411956C2 |
USING ANTI-CD20 TYPE II ANTIBODY, HAVING HIGH ANTIBODY-INDUCED CELL-DEPENDENT CYTOTOXICITY (ADCC), COMBINED WITH CYCLOPHOSPHAMIDE, VINCRISTINE AND DOXORUBICIN FOR TREATING NON-HODGKIN LYMPHOMAS | 2009 |
|
RU2589704C2 |
METHOD AND COMPOSITION FOR REDUCTION OF MICROMOLECULE AGGREGATION UNDER PHYSIOLOGICAL CONDITIONS | 2009 |
|
RU2563823C2 |
METHOD OF TREATING MULTIPLE SCLEROSIS | 2005 |
|
RU2384345C2 |
Authors
Dates
2016-11-20—Published
2011-03-09—Filed